Elan Corporation, plc today reported its third quarter 2009 financial results.
Elan CEO Kelly Martin said, “The third quarter of 2009 proved to be a time of significant transformation for Elan. Completion of the Johnson & Johnson transaction and the subsequent refinancing of our balance sheet provide strategic flexibility and financial stability for the company.” He added, “We are now afforded the opportunity to focus on growing Tysabri and EDT businesses, advancing our bioneurology pipeline and investing in unique science while having fundamentally reduced business risk across the enterprise.”
Commenting on the third quarter results, Elan executive vice president and chief financial officer, Shane Cooke said, “We are delighted with our progress this quarter, which reflect a substantial improvement in our liquidity and net debt position, as well as a continued strengthening in our operating performance. We reported net income of $52.3 million compared to a loss of $83.5 million last year. This turnaround was as a result of a net gain related to closing the Johnson & Johnson transaction and an improvement in operating performance which saw revenues grow, but operating expenses decline. Tysabri continued to show solid growth with a 19% increase in worldwide sales over last year. After the quarter-end, we further strengthened our financial position through a tender offer and new bond issue which extended the average maturity of our debt by approximately 70% and staggers it over the next 7 years.”
Mr. Cooke added that for the full year Elan remains on track to record double digit revenue growth and now expects Adjusted EBITDA of around $75 million, better than previously expected.
SOURCE Elan Corporation, plc